Author/Editor		Lešničar, Gorazd; Poljak, Mario; Luzar, Boštjan; Ferlan-Marolt, Vera; Brinovec, Vladimir; Matičič, Mojca; Meglič-Volkar, Jelka; Baklan, Zvonko; Vidmar, Ludvik; Seme, Katja; Babič, Dunja
Title		Zdravljenje bolnikov s kroničnim hepatitisom B - naše izkušnje
Type		članek
Source		In: Ferlan-Marolt V, Luzar B, editors. Viral hepatitis. Proceedings of the 35th memorial meeting to professor Janez Plečnik with international participation; 2004 Dec 2-3; Ljubljana. Ljubljana: Faculty of medicine, Institute of pathology,
Publication year		2004
Volume		str. 141-57
Language		slo
Abstract		Background. A third of world's population has serological evidence of a past or current infection with hepatitis B virus and 350 million people have chronic infection. Chronic hepatitis B is associated with liver cirrhosis and hepatic cancer, i.e the diseases that cause death in over a half million people. It is estimated that there are approximately 20.000 chronic hepatitis B virus carriers living in Slovenia. In our hospital, experimental use of interferon a for the treatment of patients with hepatitis B was started already in 1988, while the routine treatment with interferon a has been practised for ten years and with lamivudine for five years. Methods. A retrospective study carried out at the Department of Infectious Diseases and Febrile Conditions of the General Hospital Celje was aimed at evaluating the effectiveness and safety of a protocol-based treatrnent in 35 patients (21 males and 14 females, mean age 41 years) with chronic hepatitis B (11 HBeAg positive) in the period 1994 2004 receiving interferon a and/or lamivudine and since 2003 also pegylated interferon a and adefovir. In the period 2000 - 2002, there were 20 naive patients with chronic hepatitis B from three national centers in Slovenia included into an international study investigating the effectiveness and tolerability of lamivudine treatment. Results. In the period 1994 - 2000 zue treated 15 patients with chronic hepatitis B (6 HBeAg positive) using different treatment schedules: twice with interferon a, once with interferon alpha in combination with lamivudine and once with lamivudine alone, in oneyear cycles, each cycle followed by a half-year treatment free interval. (Abstract truncated at 2000 characters).
Descriptors		HEPATITIS B HEPATITIS, CHRONIC ACTIVE INTERFERON-ALPHA LAMIVUDINE HEPATITIS B E ANTIGENS DNA, VIRAL HEPATITIS B SURFACE ANTIGENS LIVER CIRRHOSIS TREATMENT OUTCOME